cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ligand Pharmaceuticals Incorporated
3 own
7 watching
Current Price
$84.95
$-1.03
(-1.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
957.24M
52-Week High
52-Week High
94.57000
52-Week Low
52-Week Low
49.24000
Average Volume
Average Volume
0.11M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
54.9356
iconMarket Capitalization957.24M
icon52-Week High94.57000
icon52-Week Low49.24000
iconAverage Volume0.11M
iconDividend Yield--
iconP/E Ratio54.9356
What does the Ligand Pharmaceuticals Incorporated do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.
Read More
How much money does Ligand Pharmaceuticals Incorporated make?
News & Events about Ligand Pharmaceuticals Incorporated.
Globe Newswire
11 months ago
One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancerSecond poster shares survey results examining vaginal and sexual health in ER+/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE NEWSWIRE) -- Sermonix ...
Globe Newswire
11 months ago
Sermonix used the Tempus TIME Trial Network to enroll 45% of its ELAINE-2 patientsThe company is again partnering with Tempus to enroll patients in its Phase 3 ELAINE-3 study COLUMBUS, Ohio, June 26, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company ...
Globe Newswire
1 year ago
VIENNA, Austria, March 15, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today presented an e-poster at the St. Gallen ...
Globe Newswire
1 year ago
Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic developmentPhase 3 study is supported by previously presented ELAINE-1 and ELAINE-2 Phase 2 study resultsSermonix anticipates dosing the first patient in first half of 2023 COLUMBUS...
Globe Newswire
1 year ago
ST. LOUIS, March 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today announced that its lead drug candidate, ...
Frequently Asked Questions
Frequently Asked Questions
What is Ligand Pharmaceuticals Incorporated share price today?
plus_minus_icon
Can Indians buy Ligand Pharmaceuticals Incorporated shares?
plus_minus_icon
How can I buy Ligand Pharmaceuticals Incorporated shares from India?
plus_minus_icon
Can Fractional shares of Ligand Pharmaceuticals Incorporated be purchased?
plus_minus_icon
What are the documents required to start investing in Ligand Pharmaceuticals Incorporated stocks?
plus_minus_icon
What is today’s traded volume of Ligand Pharmaceuticals Incorporated?
plus_minus_icon
What is today’s market capitalisation of Ligand Pharmaceuticals Incorporated?
plus_minus_icon
What is the 52-Week High and Low Range of Ligand Pharmaceuticals Incorporated?
plus_minus_icon
What percentage is Ligand Pharmaceuticals Incorporated down from its 52-Week High?
plus_minus_icon
What percentage is Ligand Pharmaceuticals Incorporated up from its 52-Week Low?
plus_minus_icon
Current Price
$84.95
$-1.03
(-1.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00